Ross Moat sold $115k of KNSA
CHIEF OPERATING OFFICER at Kiniksa Pharmaceuticals, Ltd.. 2,367 shares at an average of $48.58, traded Apr 6, 2026, filed Apr 8, 2026.
Score components
- +20RoleCOO
- +10Trade size$115k at market
- +5Share of holdings soldSold 16% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001857177-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 6, 2026 | SOpen-market sale Class A Ordinary Share10b5-1 | -2,367 | $48.58 | $115k | 12,029 | Apr 8, 2026 |
| Apr 7, 2026 | MOption exercise Class A Ordinary Share10b5-1 | +2,477 | - | - | 14,506 | Apr 8, 2026 |
| Apr 7, 2026 | FTax withholding Class A Ordinary Share10b5-1 | -774 | $48.94 | $38k | 13,732 | Apr 8, 2026 |
| Apr 7, 2026 | MOption exercise Restricted Share Unitderivative10b5-1 | -2,477 | $0.00 | $0 | 0 | Apr 8, 2026 |
Related signals
Other insiders at Kiniksa Pharmaceuticals, Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Kiniksa Pharmaceuticals, Ltd. | Michael R Megna CHIEF ACCOUNTING OFFICER | $369k 4,600 shares | -14% | |
| 34Weak | KNSAsell Kiniksa Pharmaceuticals, Ltd. | G Bradley Cole director | $299k 3,673 shares | -24% | |
| 30Weak | Kiniksa Pharmaceuticals, Ltd. | John F. Paolini CHIEF MEDICAL OFFICER | $3.1M 58,424 shares | -47% | |
| 50Moderate | Kiniksa Pharmaceuticals, Ltd. | Sanj K Patel CHAIRMAN & CEO | $2.6M 48,565 shares | -100% | |
| 50Moderate | Kiniksa Pharmaceuticals, Ltd. | Sanj K Patel CHAIRMAN & CEO | $26M 508,339 shares | -105% | |
| 35Weak | Kiniksa Pharmaceuticals, Ltd. | Barry D Quart director | $656k 13,099 shares | -51% | |
| 29Weak | Kiniksa Pharmaceuticals, Ltd. | Michael R Megna CHIEF ACCOUNTING OFFICER | $309k 6,625 shares | -19% | |
| 29Weak | Kiniksa Pharmaceuticals, Ltd. | Ross Moat CHIEF OPERATING OFFICER | $80k 1,703 shares | -12% | |
| 20Weak | Kiniksa Pharmaceuticals, Ltd. | Barry D Quart director | $345k 6,901 shares | -35% | |
| 40Moderate | Kiniksa Pharmaceuticals, Ltd. | Sanj K Patel CHAIRMAN & CEO | $364k 7,278 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.